Navigation Links
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Date:11/26/2007

ver 20 years in Germany, Austria, Switzerland, and several other countries, where it is licensed under the trade name Berinert(R) P for the treatment of acute HAE attacks.

"The successful completion of this trial confirms longstanding observations made from the administration of more than 300,000 treatments of C1-INH concentrate in Europe. We are delighted that it will now be submitted for registration in the UK," said Dr. Hilary Longhurst, Consultant Immunologist, Barts and The London NHS Trust, London, England, and investigator of the I.M.P.A.C.T. trial.

Study design and results

HAE is caused by the partial absence of functional C1 inhibitor in the blood. The objective of I.M.P.A.C.T. was to assess whether replacing the C1 protein missing in patients with HAE through treatment with C1-INH can address the underlying mechanism of the disease.

I.M.P.A.C.T. evaluated in a prospective and double-blind fashion whether different doses of human pasteurized C1-INH concentrate lead to faster relief of acute symptoms of abdominal and facial attacks compared with placebo in patients with HAE. It is also the largest dose comparison study ever done in HAE. To be eligible for inclusion in the study, patients had to be six years of age or older, with a diagnosis of C1-INH deficiency and a documented history of facial or abdominal attacks.

The primary objective was to show that C1-INH shortens the time to onset of relief of symptoms of abdominal or facial HAE attacks. The primary endpoint was time between start of C1-INH administration and onset of relief of symptoms from abdominal or facial attacks as determined by the subject's assessment. The median time to onset of relief of symptoms in the 20 U/kg b.w. C1-INH treatment group was 30 minutes, compared to 1.5 hours for patients who received placebo.

The secondary endpoint, that is, the proportion of subjects with increased intensity of clinical HAE symptoms between two and four hours aft
'/>"/>

SOURCE CSL Behring
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
5. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
6. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
7. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
8. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)... BOSTON, May 15 /- CenterWatch, a p... on market research about clinical,trials, finds t...iple EDC,(electronic data capture) systems. More t...vey indicated that they had been trained on three ...ated that the effectiveness of,their EDC training ...
(Date:5/15/2008)...onsiderable Opportunity Remains for an Antiplatele...s Bleeding than the Combination of Plavix/Iscover ...cision Resources, WALTHAM, Mass., May 15 /PRNewsw...ding research and advisory firms for pharmaceutica.../Eli Lilly,s Effient offers,improvement in patient...
(Date:5/15/2008)... Randomized TRIAS HR Pilot Study Compares Genous... Taxus(R), Other Presentations Focus on Real-Wor... with AMI, Those Who Could Not Tolerate Dual-Antip...ARCELONA, Spain, May 15 /- OrbusNeich...ntations in a symposium at EuroPCR 2008,support th...
(Date:5/14/2008)... BRISBANE, Australia, May 14 /PRNewswire-FirstCa...sdaq: PGLA) today announced that the,Company has r...ation study,of its recently acquired polyamine ana...with advanced cancer., Progen has commenced devel... the Company,s polyamine program - following its a...
Breaking Medicine Technology:CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2Heritage and Mission of Serving Children Reflected in Reintroduction of Boys Town Name and Look 8138 1Heritage and Mission of Serving Children Reflected in Reintroduction of Boys Town Name and Look 8138 2Kimberly Clark Professional Skin Care Plant Celebrates 30th Anniversary and Strong Heritage of Success in San Antonio 8134 1Kimberly Clark Professional Skin Care Plant Celebrates 30th Anniversary and Strong Heritage of Success in San Antonio 8134 2Kimberly Clark Professional Skin Care Plant Celebrates 30th Anniversary and Strong Heritage of Success in San Antonio 8134 3Pregnancy Friendly Workplace Is Key to Retaining Skilled Workers 8130 1Pregnancy Friendly Workplace Is Key to Retaining Skilled Workers 8130 2Ashlee Simpson to Read Holiday Stories to Children in Hospitals Throughout the Country Premiering Vapps Holiday Storybook Event 8126 1Ashlee Simpson to Read Holiday Stories to Children in Hospitals Throughout the Country Premiering Vapps Holiday Storybook Event 8126 2
...gression Of Atherosclerosis,In People At Low-Risk*...6-AstraZeneca today announced that the,METEOR clin...,positive effect on atherosclerosis in people with...risk of coronary heart disease,(CHD). ,The study,... at,56th Scientific Sessions of the American Colle...
...wswire/ -- Once-daily,dosing with Otsuka,s investi...receptor antagonist, was associated with improveme... heart failure (ADHF),in hospitalized patients rec...t on their long-term survival versus placebo.(1) T...es of the,international landmark trial Efficacy of...
Other Medicine Technology:First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
(Date:5/15/2008)..., 2008 -- The Society for Cardiovascular Angiogra...it will hold its 2009 Annual Scientific Sessions M...cused, collegial interventional cardiology meeting...ng time beginning in 2010. , The 2009 SCAI Annua...tional cardiology meeting of the spring for practi...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT)...ounced that, on May,12, 2008, it had received a NA...ompany,s requests for continued listing on The NAS...ed that the Company did not provide a,definitive p...mpliance with,the continued listing requirements o...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq... committed to,discovering, developing and commerci...orted unaudited financial results for the second f...orted a net loss attributable,to common stockholde...quarter ended March 31, 2008, as compared to a net...
(Date:5/15/2008)...wswire-USNewswire/ -- The American Public,Health A...r overwhelmingly,passing the 2008 farm bill and ur...egislation when it arrives on his desk., Along wi... broad,support among organizations representing th...utrition interests., "While this legislation is n...
Breaking Medicine News(10 mins):Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
... found anti-clotting drug called bivalirudin (Angi...rapy for patients with acute coronary syndromes su...s to be less risky for patients suffering from acu... the ‘Acute Catheterization and Urgent Interventio...
...e of bird flu had been discovered in a Farm in Sou...ing authorities to cull thousands more, South Kore...While speaking in a news conference, Kim Chang-sub...rantine department said: 'This case appears quite ...
...d safety officials have banned the sale of turbot ...ents in fish //at several of Beijing’s fish market...introduced by Cao Jilin from Europe in 1992. Due ...h are fed on medicinal supplements, which sometime...
...stitute for Health Information has grouped the fiv...real and Halifax into neighbourhoods, based on fiv...ants, people living alone and lone-parent families...d housing conditions and other social issues to kn...
Other Medicine News:Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Health Of Residents Is Affected by Various Factors 2
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig
... cross action. Round handle. Divides nucleus for p...ithout grooving. Nuclei of any hardness can be pre...er. Phaco of pre-chopped nuclear fragments is rapi...ving is diminished. Shortened ultra sound time and...
Karate chopper, spear shaped for ease of insertion into the nucleus.
Phaco chopper & iris retractor 2 mm cutting edge.
Medicine Products: